Beyond the Blood Sugar Story
If you ask most people what insulin does, they'll tell you it controls blood sugar. That's accurate — but it's like describing a symphony conductor as someone who holds a baton. Technically correct, and yet it misses almost everything important about the role.
Insulin is a master metabolic signaling hormone. Every tissue in the body has insulin receptors. Every organ responds to insulin's signal. When insulin signaling is healthy — characterized by the right amount of insulin released at the right times — the metabolic symphony plays in tune. When insulin signaling is chronically dysregulated, the effects ripple through every system in the body: brain, heart, peripheral nerves, fat tissue, muscle. The consequences are not confined to blood sugar.
Understanding insulin only through the lens of blood sugar is how conventional medicine misses the problem for years. Glucose stays normal — controlled by an increasingly strained pancreas pumping out ever-higher levels of insulin — while the actual metabolic damage is already well underway. By the time glucose rises, insulin resistance has typically been present for five to ten years.
"Glucose stays normal for years while insulin climbs. Conventional medicine checks glucose. Balance Medicine checks insulin."
Insulin and the Brain
The brain is not exempt from insulin signaling — it has its own insulin receptors, particularly concentrated in regions involved in memory, learning, and executive function. Insulin's role in the brain includes regulating neurotransmitter activity, supporting neuronal maintenance, and governing synaptic plasticity (the mechanism by which the brain forms and reinforces memories).
When the brain becomes resistant to insulin signaling — a condition some researchers now call Type 3 diabetes — the consequences are neurological. Brain cells that can't respond to insulin lose access to glucose despite adequate circulating levels, compromising energy supply to the neurons that need it most. The inflammatory cascade triggered by insulin resistance in peripheral tissues also reaches the brain, accelerating neuronal damage.
The research connecting insulin resistance and cognitive decline has matured significantly over the past two decades. Studies have found that people with high fasting insulin in midlife have elevated risk of cognitive impairment in later life. Elevated insulin promotes the accumulation of amyloid proteins and impairs the brain's clearance mechanisms — processes directly implicated in Alzheimer's disease pathology. This is not a fringe hypothesis; it is increasingly mainstream neuroscience.
From a clinical standpoint, this means that metabolic health is brain health. Brain fog, cognitive slowing, and memory difficulties in midlife may reflect — at least in part — an insulin signal that is no longer reaching the brain effectively.
Insulin and Cardiovascular Risk
The conventional cardiovascular risk story centers on cholesterol. But the relationship between insulin and heart disease is older, more mechanistic, and arguably more fundamental than cholesterol alone.
Elevated insulin drives endothelial dysfunction — damage to the inner lining of blood vessels that is the initiating event in atherosclerosis. High insulin promotes inflammation, and inflammatory signals are a primary driver of plaque formation and arterial stiffening. Insulin also directly stimulates smooth muscle cell proliferation in arterial walls, contributing to the thickening and stiffening of vessels over time.
The lipid pattern associated with insulin resistance is also distinct and dangerous: elevated triglycerides, low HDL cholesterol, and a shift toward smaller, denser LDL particles — which are more likely to penetrate arterial walls and contribute to plaque. This pattern, known as atherogenic dyslipidemia, is driven primarily by insulin's effect on liver fat metabolism. A standard cholesterol panel may look acceptable while this pattern is already present and progressing.
Insulin resistance also disrupts adiponectin — a hormone produced by fat tissue that has protective cardiovascular effects. As insulin resistance worsens and visceral fat accumulates, adiponectin levels fall, removing a layer of cardiovascular protection that most people never knew they had.
Insulin and the Nervous System
Peripheral neuropathy — nerve damage that causes numbness, tingling, burning pain, or loss of sensation, typically in the hands and feet — is classically associated with diabetes. What is less widely appreciated is that insulin resistance and chronically elevated insulin can drive peripheral nerve damage long before a diabetes diagnosis is ever made.
The mechanisms are multiple. Oxidative stress generated by high glucose and high insulin damages the small blood vessels (vasa nervorum) that supply peripheral nerves with oxygen and nutrients. Inflammation driven by insulin resistance affects the nerve sheaths. Advanced glycation end-products — proteins damaged by chronic glucose exposure — accumulate in nerve tissue. The result is nerve dysfunction that is already measurable in people with insulin resistance who have never been told they have a blood sugar problem.
Treating neuropathy in someone with insulin resistance by addressing only the neuropathic symptoms — with medications that manage pain without touching the underlying metabolic driver — is an example of the symptom-focused approach that conventional care defaults to. Addressing the metabolic root addresses the neuropathy at its source.
Insulin and Body Composition
Insulin is the primary hormonal switch between fat storage and fat burning. When insulin is elevated, the body is in storage mode: it directs incoming calories into fat tissue, suppresses fat mobilization, and locks cells into glucose dependency. This is the correct physiological response to a fed state. The problem arises when insulin is chronically elevated — when the signal that should be intermittent becomes constant.
This explains a clinical observation that frustrates many clients: weight that resists loss despite genuine effort. If insulin is chronically high — driven by a dietary pattern that never allows insulin to fall to low fasting levels — the body's fat-burning machinery remains suppressed regardless of caloric restriction. The metabolic environment is signaling storage, and the body complies. The solution is not more willpower or fewer calories in isolation; it is restoring the insulin rhythm that allows fat mobilization to occur.
Metabolic flexibility — the ability to switch cleanly between burning glucose and burning fat — is directly tied to insulin sensitivity. When insulin sensitivity is restored, the body regains the ability to access fat stores, stabilize energy levels, and respond appropriately to periods of reduced food intake. This is not a diet philosophy; it is physiology.
"Insulin is the primary switch between fat storage and fat burning. When it's chronically elevated, the switch is stuck on store."
What the Conventional Approach Misses
The standard metabolic workup includes fasting glucose and hemoglobin A1c. Both measure glycemic control — the downstream result of insulin's work. Neither directly measures insulin itself. This is equivalent to evaluating how hard an engine is working by only looking at the car's speed, never at the tachometer.
Checks glucose and A1c
Catches insulin resistance only after glucose rises — typically five to ten years into the problem. Acts when thresholds are crossed.
Checks fasting insulin directly
Identifies elevated insulin before glucose rises. Evaluates the full metabolic pattern and addresses the trajectory, not just the threshold.
Fasting insulin is the earliest measurable marker of insulin resistance. It rises in compensation as cells become resistant to insulin's signal — the pancreas works harder and harder to maintain normal glucose levels. Fasting insulin can be elevated for years, driving metabolic damage to the brain, heart, nerves, and fat tissue, while glucose and A1c remain entirely normal. Measuring it is not complex or expensive. It is simply not part of standard care.
At BalanceMD, fasting insulin is foundational to every metabolic evaluation. We interpret it alongside the full clinical picture: inflammatory markers, lipid patterns, hormonal context, and the client's actual history of symptoms and function. The goal is to identify where you are on the insulin signaling spectrum — not to wait until the threshold is crossed and management begins, but to understand the trajectory early enough to change it.